Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>The developer of international green fertiliser projects today announced the signing of non-binding Heads of Terms with Hy24's managed Clean H2 Infra Fund for an up to US$115m investment in the Villeta project in Paraguay.</li>
<li>Under the proposal, the Clean H2 Infra Fund will become the anchor and lead equity investor in relation to the Company's flagship 260,000 tonnes p.a. green fertiliser project.</li>
<li>The agreement marks a significant milestone towards Final Investment Decision. </li>
</ul>


The developer of international green fertiliser projects today announced the signing of non-binding Heads of Terms with Hy24's managed Clean H2 Infra Fund for an up to US$115m investment in the Villeta project in Paraguay.
Under the proposal, the Clean H2 Infra Fund will become the anchor and lead equity investor in relation to the Company's flagship 260,000 tonnes p.a. green fertiliser project.
The agreement marks a significant milestone towards Final Investment Decision. 


Research from Hardman & Co, Hardman & Co

Hardman & Co

Research from Hardman & Co

Investment research on quoted companies and funds

Hardman & Co is a multi-disciplinary financial consultancy and investment research firm, employing highly experienced analysts and professionals with a broad range of capital markets expertise. Our clients are public and private businesses as well as fund managers, ranging from start-ups to £1 billion+ market capitalisations. Hardman & Co offers corporate research & consultancy, serving the needs of both public and private companies. We produce gold-standard research with a global reach for trading and investment companies, as well as providing market commentary and analysis. In addition, we carry out a number of bespoke investment-related assignments, including due diligence on bond listings, assessments of private company valuations and other corporate advisory services. We engage with the market through traditional and digital media, offering illuminating video content on corporate management strategy, results communication, interviews and in-house sector discussion.

Oxford Nanopore Technologies / Equity Bottom-Up

<ul><li>Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.</li><li>Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.</li><li>Despite this, some companies can still make extremely attractive returns for investors.</li></ul>

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets.Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from profitability.Despite this, some companies can still make extremely attractive returns for investors.

United Kingdom

Fusion Antibodies is a Collaborative Research Organisation (CRO) specializing in antibody discovery, engineering, and supply. The company offers a range of services including antibody generation, development, production, characterization, and optimization for therapeutic drug and diagnostic applications. Fusion Antibodies is headquartered in Belfast, United Kingdom, and was established in 2001.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fusion Antibodies (FAB LN)

Hybridan Small Cap Feast: 27/02/2025

Under the proposal, the Clean H2 Infra Fund will become the anchor and lead equity investor in relation to the Company's flagship 260,000 tonnes...

Hybridan

Hardman & Co Monthly: January 2025

Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to...

Hardman & Co

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)